作者:Hideo Kitagawa、Ko Kumura、Sho Takahata、Maiko Iida、Kunio Atsumi
DOI:10.1016/j.bmc.2006.10.012
日期:2007.1
them, FabI is an enoyl-ACP reductase which catalyzes the final and rate-limiting step of bacterial FAS. It is a potential target for selective antibacterial action, because it shows low overall sequence homology with mammalian enzymes. Until today, various compounds have been reported as inhibitors of bacterial FabI-inhibitory compounds. To discover novel small-molecular FabI inhibitors, we initially
细菌FAS提供关键脂肪酸,用于关键细胞组分的组装。其中,FabI是一种烯酰ACP还原酶,可催化细菌FAS的最终和限速步骤。它是选择性抗菌作用的潜在靶标,因为它与哺乳动物酶的整体序列同源性较低。直到今天,已经报道了各种化合物作为细菌FabI抑制性化合物的抑制剂。为了发现新颖的小分子FabI抑制剂,我们首先筛选了化合物库对大肠杆菌FabI的抑制活性。并发现了4-吡啶酮衍生物作为先导化合物。结构优化研究产生了对金黄色葡萄球菌具有强FabI抑制和抗菌活性的4-吡啶酮衍生物7n。